drugset / Trial / NCT04530422
Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment
RandomizedParallel-groupSingle-blindTreatment
Summary
Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies. This study aiming to evaluate the anti-HCV medications efficacy "Sofosbuvir-Ledipasvir" in treatment of moderate cases with SARS-COV-2 infection, in comparison to the standard treatment (hydroxychloroquine, oseltamivir and azithromycin).
Timeline
- Start
- 2020-04-15
- Primary completion
- 2020-07-08
- Completion
- 2020-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | — |
| Subject | Ledipasvir | Small molecule | — | — |
| Subject | Oseltamivir | Small molecule | 150 mg | — |
| Subject | Sofosbuvir | Small molecule | — | — |